Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993804 | 0.85 | L3MBTL1 (0.48) | FEN1EGLN1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL31646056 | 0.82 | FEN1 (0.50) | FEN1EGLN1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL31304869 | 0.81 | FEN1 (0.60) | FEN1EGLN1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL968338 | 0.81 | FEN1 (0.60) | FEN1EGLN1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL4069293 | 0.81 | NPSR1 (0.39) | FEN1EGLN1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL5778708 | 0.80 | FEN1 (0.53) | FEN1EGLN1ALDH1A1 | |
| SCHEMBL4067804 | 0.80 | FEN1 (0.56) | FEN1EGLN1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL1342390 | 0.80 | FEN1 (0.56) | FEN1EGLN1KDM4EALOX15HTT | |
| SCHEMBL3244917 | 0.79 | KDM4E (0.44) | FEN1EGLN1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL3240049 | 0.79 | KDM4E (0.41) | FEN1KDM4EL3MBTL1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | claimed |
| CN-103709162-B | Tri-substituted imidazole benzodiazine ketonic compound and its production and use | 中国科学院上海药物研究所 | 2016-12-07 | — | — | CN | disclosed |
| CN-102558172-B | 5,8-bis-replaces-1,6-naphthyridine-7-amidocarbonylation compound and dimer compound thereof, Preparation Method And The Use | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-101684119-B | 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, preparing method, composite and application thereof | SHANGHAI INST MATERIA MEDICA | 2012-11-28 | — | — | CN | disclosed |
| CN-102558172-A | 5,8-disubstituted-1,6-naphthyridine-7-carbonyl amide compounds, dimer compounds of 5,8-disubstituted-1,6-naphthyridine-7-carbonyl amide compounds, and preparation method and use of 5,8-disubstituted-1,6-naphthyridine-7-carbonyl amide compounds and dimer compounds of 5,8-disubstituted-1,6-naphthyridine-7-carbonyl amide compounds | SHANGHAI INST MATERIA MEDICA | 2012-07-11 | — | — | CN | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| CN-1720238-B | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD | 2011-08-03 | — | — | CN | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030119823-A1 | Sodium salt of an HIV integrase inhibitor | MERCK & CO., INC. | 2003-06-26 | — | — | US | disclosed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | disclosed |
| WO-2003016309-A1 | PROCESS FOR PREPARING 5-SULFONAMIDO-8-HYDROXY-1, 6-NAPHTHYRIDINE-7-CARBOXAMIDES | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016294-A1 | PROCESS FOR PREPARING SULTAMS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016315-A1 | SODIUM SALT OF AN HIV INTEGRASE INHIBITOR | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | FEN1 489/4885EGLN1 3590/4885KDM4E 2029/4885 |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | FEN1 500/4885EGLN1 2027/4885KDM4E 288/4885 |
| US-20030119823-A1 | Sodium salt of an HIV integrase inhibitor | IMPA1, IMPDH1, SLC28A1 | FEN1 204/4885EGLN1 2179/4885KDM4E 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.